retatrutide ly3437943 phase 2 trial obesity nejm 2023 Retatrutide: 3 Results (Up to 28.7% Weight Loss), Mechanism, Trials & 2026 Updates Retatrutide for Obesity: Phase 2
Description
Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue
After your first injection we have a take home plan (some restrictions apply)
TRIUMPH-4 (obesity with knee osteoarthritis, no diabetes): reported December 2025, this is the data above
It's a synthetic form of growth hormone-releasing hormone (GHRH) and is often discussed in contexts relating to body composition
Schedule your consultation today for personalized care and sustainable results.
